Prescription medicine
Insulin human Brand names: Humulin, Novolin, Afrezza, Myxredlin
Insulin human (Humulin) is a prescription medicine with an FDA approval on record since 2019. No generic is listed; pharmacies paid $4.26 per mL (Humulin 70-30 vial) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the insulin human FDA label on DailyMed (effective March 7, 2025, Baxter Healthcare Corporation); the BLA 208157 record on Drugs@FDA; every insulin human label on DailyMed.
Highlights of the record
FDA label of March 7, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageMYXREDLIN is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
Forms and strengths
Injection (suspension); injection (solution); kit; powder (metered).
On the market
- Earliest approval on file
- June 20, 2019 Myxredlin, Baxter Hlthcare Corp; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 6 of which 0 under generic applications, 6 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $4.26 per mL Humulin 70-30 vial
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2026 0 Class I among all firms' recalls; latest August 6, 2026
- FAERS reports
- 46,071 through July 30, 2026
What is insulin human used for?
From the label: indications and usageMYXREDLIN is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. MYXREDLIN is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus ( 1 ).
Conditions named in the indications of insulin human's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Insulin.
Source: FDA drug label (MYXREDLIN), Baxter Healthcare Corporation, effective March 7, 2025 (SPL set afca6e80-a802-49fb-a978-5fe28a173001), via openFDA; the full label on DailyMed
What does the patient leaflet for insulin human say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about AFREZZA?AFREZZA can cause serious side effects, including: Sudden lung problems (bronchospasms). Do not use AFREZZA if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD). Before starting AFREZZA, your healthcare provider will give you a breathing test to check how your lungs are working.
From the patient leaflet: What should I avoid while using AFREZZA?While using AFREZZA do not: Drive or operate heavy machinery, until you know how AFREZZA affects you. Drink alcohol or use over-the-counter medicines that contain alcohol. Smoke.
Source: FDA drug label (AFREZZA), Mannkind Corporation, effective May 30, 2026 (SPL set 29f4637b-e204-425b-b89c-7238008d8c10), via openFDA; the full label on DailyMed
Is there a generic for insulin human (Humulin)?
No generic insulin human is approved (Drugs@FDA, October 8, 2026).
- 2019 earliest approval on file
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for insulin human (Humulin)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $4.26 per mL (Humulin 70-30 vial), about the same as a year earlier. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Humulin 70-30 vial (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Afrezza ((regular insulin) 8 unit cartridge | Brand | $10.38 per cartridge | n/a | +3% |
| Afrezza (regular insulin) 12 unit cartridge | Brand | $15.65 per cartridge | n/a | +3% |
| Afrezza (regular insulin) 4 unit cartridge | Brand | $5.21 per cartridge | n/a | +2% |
| Afrezza (regular insulin) 60-4 unit/60-8 unit/60-12 unit | Brand | $10.33 per unit | n/a | +2% |
| Afrezza (regular insulin) 90-4 unit / 90-8 unit | Brand | $7.78 per unit | n/a | +2% |
| Afrezza (regular insulin) 90-8 unit / 90-12 unit | Brand | $13.04 per unit | n/a | +3% |
| Humulin 70-30 vial | Brand | $4.26 per mL | n/a | -0.3% |
| Humulin 70/30 kwikpen | Brand | $9.03 per mL | n/a | no change |
| Humulin n 100 unit/mL kwikpen | Brand | $9.03 per mL | n/a | -0.1% |
| Humulin n 100 unit/mL vial | Brand | $4.27 per mL | n/a | -0.2% |
| Humulin r 100 unit/mL vial | Brand | $4.26 per mL | n/a | -0.1% |
| Humulin r 500 unit/mL kwikpen | Brand | $91.61 per mL | n/a | -0.1% |
| Novolin 70-30 100 unit/mL vial | Brand | $4.63 per mL | n/a | -0.1% |
| Novolin 70-30 flexpen | Brand | $5.83 per mL | n/a | no change |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has insulin human been recalled?
The FDA's Enforcement Report lists 1 recall naming insulin human since 2026: 0 Class I (the most serious), 1 Class II, 0 Class III; 1 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| August 6, 2026 | Class II | Baxter Healthcare Corporation | CGMP Deviations |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the insulin human label say about other medicines?
The insulin human label names 17 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Albuterol | drug interactions | … progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when MYXREDLIN is co-administered with these drugs. |
| Clonidine | drug interactions | Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of MYXREDLIN Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. |
| Clozapine | drug interactions | Drugs that May Decrease the Blood Glucose Lowering Effect of MYXREDLIN Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Danazol | drug interactions | Drugs that May Decrease the Blood Glucose Lowering Effect of MYXREDLIN Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Disopyramide | drug interactions | Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. … |
| Epinephrine | drug interactions | … (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when MYXREDLIN is co-administered with these drugs. |
| Fluoxetine | drug interactions | Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. … |
| Glucagon | drug interactions | Drugs that May Decrease the Blood Glucose Lowering Effect of MYXREDLIN Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Isoniazid | drug interactions | Drugs that May Decrease the Blood Glucose Lowering Effect of MYXREDLIN Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Lithium | drug interactions | Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of MYXREDLIN Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. |
| Niacin | drug interactions | Drugs that May Decrease the Blood Glucose Lowering Effect of MYXREDLIN Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Octreotide | drug interactions | Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. … |
| Olanzapine | drug interactions | Drugs that May Decrease the Blood Glucose Lowering Effect of MYXREDLIN Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Pentoxifylline | drug interactions | Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. … |
Every other medicine the insulin human label names
| Medicine named | Section | What the label says |
|---|---|---|
| Pramlintide | drug interactions | … fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. … |
| Somatropin | drug interactions | … progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. … |
| Terbutaline | drug interactions | … somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when … |
Source: FDA drug label (MYXREDLIN), Baxter Healthcare Corporation, effective March 7, 2025 (SPL set afca6e80-a802-49fb-a978-5fe28a173001), via openFDA; the full label on DailyMed
What do FAERS reports show for insulin human?
The FDA Adverse Event Reporting System holds 46,071 reports that list insulin human among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 3,681 are coded as a death and 15,618 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as insulin human?
14 other medicines are given the same way (subcutaneous) and in the same FDA class as insulin human or labeled mainly for the same use (type 2 diabetes), the same class first. Type 2 diabetes lists all 52 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Tirzepatide | Type 2 diabetes | none listed | $538.68 per mL 10 mg/0.5 mL pen | No current entry |
| Insulin glargine | Type 2 diabetes, Type 1 diabetes | none listed | $2.90 per mL 100 pen | A presentation being discontinued |
| Liraglutide | Type 2 diabetes | 9 labelers | $31.41 per mL 2-pak 18 mg/3 mL | In shortage |
| Insulin aspart | Type 2 diabetes, Type 1 diabetes | none listed | $6.95 per mL 100 unit/mL vial | No current entry |
| Insulin lispro | Type 2 diabetes, Type 1 diabetes | none listed | $10.19 per mL 100 unit/mL kwikpen | A presentation being discontinued |
| Semaglutide | Type 2 diabetes | none listed | $331.99 per mL 0.25-0.5 mg/dose (2 mg/3 mL) pen | A presentation being discontinued |
| Dulaglutide | Type 2 diabetes | none listed | $487.57 per mL 0.75 mg/0.5 mL pen | No current entry |
| Insulin degludec | Type 2 diabetes, Type 1 diabetes | none listed | $11.39 per mL 100 unit/mL pen | No current entry |
Every medicine labeled for the same conditions as insulin human
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to insulin human
- 14 medicines for the same use
- Insulin human side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other